Literature DB >> 36000876

Agglutination of Borreliella burgdorferi by Transmission-Blocking OspA Monoclonal Antibodies and Monovalent Fab Fragments.

Amber M Frye1, Monir Ejemel2, Lisa Cavacini2, Yang Wang2, Michael J Rudolph3, Renjie Song4, Nicholas J Mantis1,4.   

Abstract

Lyme disease vaccines based on recombinant Outer surface protein A (OspA) elicit protective antibodies that interfere with tick-to-host transmission of the disease-causing spirochete Borreliella burgdorferi. Another hallmark of OspA antisera and certain OspA monoclonal antibodies (MAbs) is their capacity to induce B. burgdorferi agglutination in vitro, a phenomenon first reported more than 30 years ago but never studied in molecular detail. In this report, we demonstrate that transmission-blocking OspA MAbs, individually and in combination, promote dose-dependent and epitope-specific agglutination of B. burgdorferi. Agglutination occurred within minutes and persisted for hours. Spirochetes in the core of the aggregates exhibited evidence of outer membrane (OM) stress, revealed by propidium iodide uptake. The most potent agglutinator was the mouse MAb LA-2, which targets the OspA C terminus (β-strands 18 to 20). Human MAb 319-44, which also targets the OspA C terminus (β-strand 20), and 857-2, which targets the OspA central β-sheet (strands 8 to 10), were less potent agglutinators, while MAb 221-7, which targets β-strands 10 to 11, had little to no measurable agglutinating activity, even though its affinity for OspA exceeded that of LA-2. Remarkably, monovalent Fab fragments derived from LA-2, and to a lesser degree 319-44, retained the capacity to induce B. burgdorferi aggregation and OM stress, a particularly intriguing observation considering that "LA-2-like" Fabs have been shown to experimentally entrap B. burgdorferi within infected ticks and prevent transmission during feeding to a mammalian host. It is therefore tempting to speculate that B. burgdorferi aggregation triggered by OspA-specific antibodies in vitro may in fact reflect an important biological activity in vivo.

Entities:  

Keywords:  antibody; protective; spirochete; vaccines

Mesh:

Substances:

Year:  2022        PMID: 36000876      PMCID: PMC9476992          DOI: 10.1128/iai.00306-22

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.609


  63 in total

Review 1.  Approaches toward the directed design of a vaccine against Borrelia burgdorferi.

Authors:  Benjamin J Luft; John J Dunn; Catherine L Lawson
Journal:  J Infect Dis       Date:  2002-02-15       Impact factor: 5.226

2.  Atomic-resolution crystal structure of Borrelia burgdorferi outer surface protein A via surface engineering.

Authors:  Koki Makabe; Valentina Tereshko; Grzegorz Gawlak; Shude Yan; Shohei Koide
Journal:  Protein Sci       Date:  2006-07-05       Impact factor: 6.725

3.  Structural investigation of Borrelia burgdorferi OspB, a bactericidal Fab target.

Authors:  Michael Becker; Jonas Bunikis; Barbara D Lade; John J Dunn; Alan G Barbour; Catherine L Lawson
Journal:  J Biol Chem       Date:  2005-02-15       Impact factor: 5.157

4.  Antigenic and genetic heterogeneity of Borrelia burgdorferi populations transmitted by ticks.

Authors:  J Ohnishi; J Piesman; A M de Silva
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-16       Impact factor: 11.205

5.  Immunogenicity of the Lyme disease antigen OspA, particleized by cobalt porphyrin-phospholipid liposomes.

Authors:  Jasmin Federizon; Amber Frye; Wei-Chiao Huang; Thomas M Hart; Xuedan He; Christopher Beltran; Ashley L Marcinkiewicz; Iain L Mainprize; Melanie K B Wills; Yi-Pin Lin; Jonathan F Lovell
Journal:  Vaccine       Date:  2019-11-11       Impact factor: 3.641

6.  Outer-surface protein C of the Lyme disease spirochete: a protein induced in ticks for infection of mammals.

Authors:  Dorothee Grimm; Kit Tilly; Rebecca Byram; Philip E Stewart; Jonathan G Krum; Dawn M Bueschel; Tom G Schwan; Paul F Policastro; Abdallah F Elias; Patricia A Rosa
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-17       Impact factor: 11.205

7.  The lipid raft proteome of Borrelia burgdorferi.

Authors:  Alvaro Toledo; Alberto Pérez; James L Coleman; Jorge L Benach
Journal:  Proteomics       Date:  2015-09-28       Impact factor: 3.984

8.  The bactericidal effect of a complement-independent antibody is osmolytic and specific to Borrelia.

Authors:  Timothy J LaRocca; David J Holthausen; Chyongere Hsieh; Christian Renken; Carmen A Mannella; Jorge L Benach
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-19       Impact factor: 11.205

9.  Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group.

Authors:  A C Steere; V K Sikand; F Meurice; D L Parenti; E Fikrig; R T Schoen; J Nowakowski; C H Schmid; S Laukamp; C Buscarino; D S Krause
Journal:  N Engl J Med       Date:  1998-07-23       Impact factor: 91.245

10.  Isolation and Characterization of Human Monoclonal Antibodies to Pneumococcal Capsular Polysaccharide 3.

Authors:  Rachelle Babb; Christopher R Doyle; Liise-Anne Pirofski
Journal:  Microbiol Spectr       Date:  2021-11-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.